PRDM1 and autoimmune disease: Notably, Blimp-1 has demonstrated therapeutic potential in autoimmune disease models by modulating Th1/Th17 differentiation and Treg function, suggesting that SCFA-mediated Blimp-1 activation may offer novel immunosuppressive therapeutic strategies [57].